Follow RSS for latest reports on this topicStatins - Market Research and Reports
Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Increased cholesterol levels have been associated with cardiovascular diseases (CVD), and statins are therefore used in the prevention of these diseases. Randomized controlled trials have shown that they are most effective in those already suffering from cardiovascular disease (secondary prevention), but they are also advocated and used extensively in those without previous CVD but with elevated cholesterol levels and other risk factors (such as diabetes and high blood pressure) that increase a person's risk.
The best-selling of the statins is atorvastatin, marketed as Lipitor and manufactured by Pfizer. By 2003 it had become the best-selling pharmaceutical in history, with Pfizer reporting sales of $12.4 billion in 2008. As of 2010, a number of statins are on the market: atorvastatin (Lipitor and Torvast), fluvastatin (Lescol), lovastatin (Mevacor, Altocor, Altoprev), pitavastatin (Livalo, Pitava), pravastatin (Pravachol, Selektine, Lipostat), rosuvastatin (Crestor) and simvastatin (Zocor, Lipex). Several combination preparations of a statin and another agent—such as ezetimibe/simvastatin, sold as Vytorin.
BioPortfolio's Easy Ordering System
- Search for the report you need from our store
- Make online payment with our easy checkout process
- Receive PDF report via email
Easy Online Payment or Pro Forma Invoice
We accept the following credit cards...
or can supply a pro-forma invoice if required.
We found 1 reports that matched your search.
Refine your search, and find more matches, using the form above.
Physician Views: Life beyond statins – what opportunity for PCSK9 inhibitors?
ScopeWith Sanofi and Regeneron Pharmaceuticals set to unveil the first Phase III data for their experimental PCSK9 inhibitor alirocumab imminently, expectation for this class of therapies is set to rise even further over the coming months. Shaped by positive Phase II results, analysts expect the peak market opportunity for PCSK9 inhibitors to be worth between billion and billion. Amgen is p...Read More >>>
Published by: FirstWord Pharma
Prices Starting From: